Amarin Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa(R)

Amarin Announces Notification of Patent Allowance for U.S. Application
13/417,899 Related to Combination Product of Vascepa(R) and Statin Therapy

Further Broadens Scope of Claims Covering Co-Administration of Vascepa and
Statin to Reduce Triglycerides

BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced today that the United States Patent and Trademark Office
(USPTO) has published notification of a Notice of Allowance for Amarin's U.S.
Patent Application Serial Number 13/417,899 titled "Pharmaceutical
Compositions Comprising EPA and a Cardiovascular Agent and Methods of Using
the Same." This application includes claims intended to protect the Vascepa^®
(icosapent ethyl) indication approved by the U.S. Food and Drug Administration
(FDA) based on Amarin's MARINE clinical trial results specifically those
results seen in patients on statin therapy.

The claims in this allowed application cover a method to reduce triglycerides
in subjects having a triglyceride level of 500mg/dl to 1500mg/dl who are also
receiving statin therapy (whether in fixed or non-fixed dose formulation)
using an amount of Vascepa effective to reduce triglycerides without
substantially increasing low density lipoprotein cholesterol (LDL-C). 

"Through our findings from conversations with thought leaders and other
clinicians during the launch of Vascepa, we've confirmed that many patients on
therapies intended for lowering triglycerides are also on statins. The claims
in this allowed application cover the administration of a pharmaceutical
composition comprised of EPA in conjunction with a stain, using either a fixed
or non-fixed dose, to lower triglycerides without increasing LDL-C, otherwise
known as bad-cholesterol," stated Joseph Zakrzewski, Chairman and Chief
Executive Officer of Amarin.

A Notice of Allowance is issued after the USPTO makes a determination that a
patent can be granted from an application. The issued patent would have a term
that expires no earlier than in 2030. Amarin plans to list this patent in the
FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or
Orange Book, after issuance of the patent.

This application is part of an expanding patent portfolio for Amarin with 23
patent applications now either issued or allowed with the USPTO and over 30
additional applications pending in the United States. Amarin is also pursuing
patent applications related to Vascepa in multiple jurisdictions outside the
United States, including the application for Amarin's MARINE method of use
patent in Europe for which Amarin has announced receipt of an Intention to
Grant letter.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA and available by prescription. For more
information about Vascepa visit www.vascepa.com. For more information about
Amarin visit www.amarincorp.com.

Forward-looking statements

This press release contains forward-looking statements, including statements
about whether the subject patent would be issued and adequately protect
Vascepa against competition, the expiration date of the pending patent,
Amarin's plan to list the patent, when issued, in FDA's Orange Book, Amarin's
plan to protect the commercial potential of Vascepa, the future status of
pending patent applications, planned regulatory submissions and expected
action dates. These forward-looking statements are not promises or guarantees
and involve substantial risks and uncertainties. Among the factors that could
cause actual results to differ materially from those described or projected
herein include the following: events that could interfere with the issuance of
a patent, or once issued, the continued validity or enforceability of a
patent; Amarin's ability generally to maintain adequate patent protection and
successfully enforce patent claims against third parties; commercializing
Vascepa without violating the intellectual property rights of others; and
uncertainties associated generally with research and development, clinical
trial enrollment in Amarin's REDUCE-IT trial and related regulatory
submissions, action dates and approvals. A further list and description of
these risks, uncertainties and other risks associated with an investment in
Amarin can be found in Amarin's filings with the U.S. Securities and Exchange
Commission, including its most recent Quarterly Report on Form 10-Q. Existing
and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin
undertakes no obligation to update or revise the information contained in this
press release, whether as a result of new information, future events or
circumstances or otherwise.

CONTACT: Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.